Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients

作者: Hideyuki Akaza , Seiji Naito , Naomi Ueno , Kouji Aoki , Hiroyuki Houzawa

DOI: 10.1093/JJCO/HYV045

关键词:

摘要: Objective: This prospective, post-marketing study collected sunitinib safety and efficacy data in Japanese patients with unresectable/metastatic renal cell carcinoma. Retrospective analysis investigated adverse events as potential biomarkers. Methods: Patients administered sunitinib, after its release, were registered until reaching a pre-specified number of cases. Primary starting dose was 50 mg/day orally on 4-weeks-on 2-weeks-off schedule. Physicians completed investigation forms at 6-week intervals for 24 weeks. Associations between baseline characteristics analyzed by Cox proportional hazards model compared χ 2 test. The log-rank test survival subpopulations based selected factors. Results: Of note, 1689 receiving June 2008 November 2009. Most them males (75%), aged <65 years (56%), had Eastern Cooperative Oncology Group performance status 0/1 (90%), metastatic disease (88%) previous systemic therapy (66%). Grade ≥3 occurred 70%, reduced platelet count the most common (34%). Characteristics significantly associated female sex, age ≥55 years, ≥2, history several medical conditions prior treatment. Objective response rate 22%. Median progression-free 22.7 overall not reached; however, 24-weekoverall ratewas 84%. Improved higher relative intensity during first 6 weeks specific events: hypertension, hand–foot syndrome, hypothyroidism, leukopenia thrombocytopenia. Conclusions: Sunitinib demonstrated acceptable useful Potential biomarkers greater events.

参考文章(21)
Manuela Schmidinger, Ursula M. Vogl, Marija Bojic, Wolfgang Lamm, Harald Heinzl, Andrea Haitel, Martin Clodi, Gero Kramer, Christoph C. Zielinski, Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer. ,vol. 117, pp. 534- 544 ,(2011) , 10.1002/CNCR.25422
F. Donskov, A. Cams, C.H. Barrios, B. Escudier, S. Li, J. Perkins, R.J. Motzer, 1141 POSTER Neutropenia and Thrombocytopenia During Treatment as Biomarkers of Sunitinib Efficacy in Patients With Metastatic Renal Cell Carcinoma (mRCC) European Journal of Cancer. ,vol. 47, ,(2011) , 10.1016/S0959-8049(11)70784-5
Hui Shan Tan, Huihua Li, Yu Wen Hong, Chee-Keong Toh, Alvin Wong, Gilberto Lopes, Miah Hiang Tay, Alexandre Chan, Xin Yao, Tiffany Tang, Quan Sing Ng, Ravindran Kanesvaran, Noan Minh Chau, Min-Han Tan, Efficacy and Safety of an Attenuated-Dose Sunitinib Regimen in Metastatic Renal Cell Carcinoma: Results From a Prospective Registry in Singapore. Clinical Genitourinary Cancer. ,vol. 13, pp. 285- 295 ,(2015) , 10.1016/J.CLGC.2014.11.004
Carlos H Barrios, David Hernandez‐Barajas, Michael P Brown, Se‐Hoon Lee, Luis Fein, Jin‐Hwang Liu, Subramanian Hariharan, Bridget A Martell, Jinyu Yuan, Akintunde Bello, Zhixiao Wang, Rajiv Mundayat, Sun‐Young Rha, None, Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. Cancer. ,vol. 118, pp. 1252- 1259 ,(2012) , 10.1002/CNCR.26440
Georg A. Bjarnason, Bishoy Khalil, John M. Hudson, Ross Williams, Laurent M. Milot, Mostafa Atri, Alex Kiss, Peter N. Burns, Reprint of: Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: Correlation with dynamic microbubble ultrasound data and review of the literature Urologic Oncology-seminars and Original Investigations. ,vol. 33, pp. 171- 178 ,(2014) , 10.1016/J.UROLONC.2015.03.003
S. Lee, H.C. Chung, P. Mainwaring, C. Ng, J.W.C. Chang, P. Kwong, R.K. Li, V. Sriuranpong, C.K. Toh, S. Pitman Lowenthal, 7118 An Asian subpopulation analysis of the safety and efficacy of sunitinib in metastatic renal cell carcinoma Ejc Supplements. ,vol. 7, pp. 428- ,(2009) , 10.1016/S1359-6349(09)71451-X
Y.G. Najjar, K. Mittal, P. Elson, L. Wood, J.A. Garcia, R. Dreicer, B.I. Rini, A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma European Journal of Cancer. ,vol. 50, pp. 1084- 1089 ,(2014) , 10.1016/J.EJCA.2014.01.025
H. Uemura, N. Shinohara, T. Yuasa, Y. Tomita, H. Fujimoto, M. Niwakawa, S. Mugiya, T. Miki, N. Nonomura, M. Takahashi, Y. Hasegawa, N. Agata, B. Houk, S. Naito, H. Akaza, A Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma: Insights into the Treatment, Efficacy and Safety Japanese Journal of Clinical Oncology. ,vol. 40, pp. 194- 202 ,(2010) , 10.1093/JJCO/HYP146
Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak, M. Dror Michaelson, Ronald M. Bukowski, Stéphane Oudard, Sylvie Negrier, Cezary Szczylik, Roberto Pili, Georg A. Bjarnason, Xavier Garcia-del-Muro, Jeffrey A. Sosman, Ewa Solska, George Wilding, John A. Thompson, Sindy T. Kim, Isan Chen, Xin Huang, Robert A. Figlin, Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma Journal of Clinical Oncology. ,vol. 27, pp. 3584- 3590 ,(2009) , 10.1200/JCO.2008.20.1293
Daniel Y.C. Heng, Wanling Xie, Meredith M. Regan, Mark A. Warren, Ali Reza Golshayan, Chakshu Sahi, Bernhard J. Eigl, J. Dean Ruether, Tina Cheng, Scott North, Peter Venner, Jennifer J. Knox, Kim N. Chi, Christian Kollmannsberger, David F. McDermott, William K. Oh, Michael B. Atkins, Ronald M. Bukowski, Brian I. Rini, Toni K. Choueiri, Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study Journal of Clinical Oncology. ,vol. 27, pp. 5794- 5799 ,(2009) , 10.1200/JCO.2008.21.4809